Targeted Prostate Biopsy Using 68Gallium PSMA-PET/CT for Image Guidance

Demetrios N Simopoulos; Shyam Natarajan; Tonye A Jones; Wolfgang P Fendler; Anthony E Sisk Jr; Leonard S Marks

doi:10.1016/j.eucr.2017.05.006

Targeted Prostate Biopsy Using ⁶⁸Gallium PSMA-PET/CT for Image Guidance

Urol Case Rep. 2017 Jun 3:14:11-14. doi: 10.1016/j.eucr.2017.05.006. eCollection 2017 Sep.

Authors

Demetrios N Simopoulos¹, Shyam Natarajan¹, Tonye A Jones¹, Wolfgang P Fendler², Anthony E Sisk Jr³, Leonard S Marks¹

Affiliations

¹ Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, 300 Stein Plaza, 3rd Floor, Los Angeles, CA 90095, USA.
² Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, 10833 Le Conte Avenue, 200 Medical Plaza, Suite B114-61, Los Angeles, CA 90095, USA.
³ Department of Pathology, David Geffen School of Medicine, University of California at Los Angeles, 10833 LeConte Avenue, A3-240 CHS, Los Angeles, CA 90095, USA.

Abstract

Prostate specific membrane antigen (PSMA) scanning is a sensitive method of prostate cancer detection. In a 71 y.o. man with a PSA of 49 (6%F), 4 negative MRI studies and 6 negative biopsies over an 8 year interval, a ⁶⁸Ga-PSMA PET/CT scan showed a PSMA-avid spot in the prostate. Using image fusion technology, the lesion was target-biopsied and Gleason 3 + 4 = 7 (cancer core length of 12 mm) was identified. This case may herald a new application for PSMA scanning and prostate cancer imaging.

Keywords: 68Ga, 68Gallium; CaP, prostate cancer; PSMA; PSMA, prostate specific membrane antigen; Prostate cancer; ROI, region of interest; Targeted biopsy; mpMRI; mpMRI, multiparametric MRI.

Publication types

Case Reports